AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of -0.420–0.380 for the period, compared to the consensus estimate of -0.410. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $284.4 million. AngioDynamics also updated its FY25 guidance to ($0.42)-($0.38) EPS.

AngioDynamics Trading Down 4.2 %

Shares of NASDAQ ANGO opened at $6.10 on Friday. The firm has a market capitalization of $244.34 million, a price-to-earnings ratio of -1.26 and a beta of 0.65. AngioDynamics has a one year low of $5.26 and a one year high of $8.25. The business has a fifty day simple moving average of $7.48 and a 200 day simple moving average of $6.62.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The firm’s revenue for the quarter was down 14.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) EPS. On average, research analysts anticipate that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ANGO shares. HC Wainwright reiterated a buy rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday. Canaccord Genuity Group lowered their price target on AngioDynamics from $13.00 to $12.00 and set a buy rating on the stock in a research report on Friday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics presently has an average rating of Moderate Buy and an average target price of $12.00.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.